TapewireFind a company

person · Reporting owner

Lecault Veronique

Disclosed activity across 1 company

Tapewire entity
70241
SEC CIK
0001834418

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
AbCellera Biologics Inc.ABCL · Entity 4118Director · Chief Technology OfficerJanuary 01, 2026January 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AbCellera Biologics Inc.

Report date January 01, 2026 · Filed January 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2036-01-01Direct5,201,069 Reported balance After 2026-01-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-01 · Grant · Acquired 539,265 · Balance 5,201,069

F1: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 01, 2026 Filed Jan 5, 2026 17:08 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantShare option (right to buy) · Derivative 539,265 $0.00 Strike: $3.42 $0.00
Disclosure

SEC source: 0001834418-26-000002 · wk-form4_1767632934.xml · derivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,201,069

Underlying: Common Shares · 539,265 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
January 01, 2025 Filed Jan 3, 2025 20:40 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantShare option (right to buy) · Derivative 832,033 $0.00 Strike: $2.93 $0.00
Disclosure

SEC source: 0001628280-25-000235 · wk-form4_1735936840.xml · derivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,661,804

Underlying: Common Shares · 832,033 shares

Expires 2035-01-01

F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
June 21, 2024 Filed Jun 24, 2024 22:38 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 83,334 $0.00 Strike: $0.19 $0.00
Disclosure

SEC source: 0001628280-24-029675 · wk-form4_1719268705.xml · derivative · entry 5

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,829,771

Underlying: Common Shares · 83,334 shares

Expires 2027-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
June 21, 2024 Filed Jun 24, 2024 22:38 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 83,334 $0.19 $15,666.79
Disclosure

SEC source: 0001628280-24-029675 · wk-form4_1719268705.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,123,456

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 14, 2024 Filed Jan 16, 2024 23:23 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantShare option (right to buy) · Derivative 770,416 $0.00 Strike: $5.39 $0.00
Disclosure

SEC source: 0001703057-24-000008 · wk-form4_1705447421.xml · derivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,913,105

Underlying: Common Shares · 770,416 shares

Expires 2034-01-14

F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 14, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
September 12, 2023 Filed Sep 14, 2023 20:38 UTC AbCellera Biologics Inc. ABCL · Entity 4118 PurchaseCommon Shares 20,000 $5.19 $103,800.00
Disclosure

SEC source: 0001703057-23-000030 · wk-form4_1694723915.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,040,122

Read SEC document
May 05, 2023 Filed May 9, 2023 19:02 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 250,000 $0.00 Strike: $0.19 $0.00
Disclosure

SEC source: 0001209191-23-028214 · doc4.xml · derivative · entry 5

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,142,689

Underlying: Common Shares · 250,000 shares

Expires 2027-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
May 05, 2023 Filed May 9, 2023 19:02 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 250,000 $0.19 $47,500.00
Disclosure

SEC source: 0001209191-23-028214 · doc4.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,020,122

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 01, 2022 Filed Dec 5, 2022 17:28 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantShare Options (right to buy) · Derivative 462,535 $0.00 Strike: $13.18 $0.00
Disclosure

SEC source: 0001209191-22-059573 · doc4.xml · derivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,392,689

Underlying: Common Shares · 462,535 shares

Expires 2032-12-01

F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
May 16, 2022 Filed May 17, 2022 19:07 UTC AbCellera Biologics Inc. ABCL · Entity 4118 PurchaseCommon Shares 200,000 $6.34 $1,267,780.00
Disclosure

SEC source: 0001209191-22-029542 · doc4.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,770,122

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $6.22 to $6.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 00:49 UTC AbCellera Biologics Inc. ABCL · Entity 4118 PurchaseCommon Shares 230,789 $8.66 $1,998,632.74
Disclosure

SEC source: 0001209191-22-014395 · doc4.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,570,122

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased at prices ranging from $8.48 to $8.80. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Read SEC document
December 08, 2021 Filed Dec 9, 2021 22:49 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare Option (right to buy) · Derivative 250,000 $0.00 Strike: $0.19 $0.00
Disclosure

SEC source: 0001209191-21-068844 · doc4.xml · derivative · entry 5

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,524,134

Underlying: Common Shares · 250,000 shares

Expires 2027-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
December 08, 2021 Filed Dec 9, 2021 22:49 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 250,000 $0.19 $47,500.00
Disclosure

SEC source: 0001209191-21-068844 · doc4.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,589,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 08, 2021 Filed Feb 4, 2022 00:00 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GiftCommon Shares 250,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-006972 · doc5.xml · nonDerivative · entry 2

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,339,333

F2 · shares: This transaction represents a charitable donation of 250,000 common shares the reporting person donated on December 8, 2021.

Read SEC document
December 07, 2021 Filed Dec 9, 2021 23:01 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantShare Option · Derivative 406,020 $0.00 Strike: $14.55 $0.00
Disclosure

SEC source: 0001209191-21-068851 · doc4.xml · derivative · entry 5

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,930,154

Underlying: Common Shares · 406,020 shares

Expires 2031-12-07

F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date

Read SEC document
November 30, 2021 Filed Dec 2, 2021 19:16 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare Option (right to buy) · Derivative 83,333 $0.00 Strike: $0.19 $0.00
Disclosure

SEC source: 0001209191-21-067491 · doc4.xml · derivative · entry 5

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,774,134

Underlying: Common Shares · 83,333 shares

Expires 2027-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
November 30, 2021 Filed Dec 2, 2021 19:16 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 83,333 $14.96 $1,246,661.68
Disclosure

SEC source: 0001209191-21-067491 · doc4.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,422,666

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 30, 2021 Filed Dec 3, 2021 22:47 UTC Amendment AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare Option (right to buy) · Derivative 83,333 $0.00 Strike: $0.19 $0.00
Disclosure

SEC source: 0001209191-21-067941 · doc4a.xml · derivative · entry 5

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,774,134

Underlying: Common Shares · 83,333 shares

Expires 2027-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
November 30, 2021 Filed Dec 3, 2021 22:47 UTC Amendment AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 83,333 $0.19 $15,833.27
Disclosure

SEC source: 0001209191-21-067941 · doc4a.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,422,666

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The original price was listed as $14.96 which is an administrative error. The correct price is $0.19.

Read SEC document
November 30, 2021 Filed Feb 4, 2022 00:00 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GiftCommon Shares 83,333 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-006972 · doc5.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,339,333

F1 · shares: This transaction represents a charitable donation of 83,333 common shares the reporting person donated on November 30, 2021.

Read SEC document
June 15, 2021 Filed Jun 17, 2021 00:00 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare Option (right to buy) · Derivative 333,333 $0.00 Strike: $0.19 $0.00
Disclosure

SEC source: 0000899243-21-024295 · doc4.xml · derivative · entry 5

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 666,667

Underlying: Common Shares · 333,333 shares

Expires 2027-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.333:USD $1.00 for March 23, 2017 as set forth on Bloomberg.

F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on November 8, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date.

F5 · derivative.expiration_date: Expiration date corrected from the date listed on the Form 3 filed on December 11, 2020.

Read SEC document
June 15, 2021 Filed Jun 17, 2021 00:00 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 333,333 $0.19 $63,333.27
Disclosure

SEC source: 0000899243-21-024295 · doc4.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,339,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Per share exercise price has been converted from CAD to USD based on the grant date exchange ratio of CAD $1.333:USD $1.00 for March 23, 2017 as set forth on Bloomberg.

Read SEC document
June 09, 2021 Filed Jun 10, 2021 21:01 UTC AbCellera Biologics Inc. ABCL · Entity 4118 SaleCommon Shares 1,000,000 $25.50 $25,500,000.00
Disclosure

SEC source: 0000899243-21-022990 · doc4.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 273,630

F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50.

F2 · kind: The sale of the shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), to the extent of 23,000 shares, with the purchase by the Reporting Person of 6,000 shares at a price of $20 per share on December 15, 2020, and the purchase by the Reporting Person's spouse of 17,000 shares at a price of $20 per share on December 15, 2020, as reported previously on the Reporting Person's Form 4 filed on December 17, 2020. The Reporting Person has voluntarily disgorged to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act.

F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50.

F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50.

F3 · ownership.nature: These shares are held by Slomo Family Trust. The Reporting Person is a co-trustee of the Slomo Family Trust. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.

Read SEC document
December 15, 2020 Filed Dec 18, 2020 01:30 UTC AbCellera Biologics Inc. ABCL · Entity 4118 PurchaseCommon Shares 17,000 $20.00 $340,000.00
Disclosure

SEC source: 0000899243-20-034342 · doc4.xml · nonDerivative · entry 2

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 61,580

Read SEC document
December 15, 2020 Filed Dec 18, 2020 01:30 UTC AbCellera Biologics Inc. ABCL · Entity 4118 PurchaseCommon Shares 6,000 $20.00 $120,000.00
Disclosure

SEC source: 0000899243-20-034342 · doc4.xml · nonDerivative · entry 1

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,006,000

Read SEC document
December 10, 2020 Filed Dec 18, 2020 01:30 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantStock Option (right to buy) · Derivative 190,800 $0.00 Strike: $20.00 $0.00
Disclosure

SEC source: 0000899243-20-034342 · doc4.xml · derivative · entry 6

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,800

Underlying: Common Shares · 190,800 shares

Expires 2030-12-10

F7 · kind: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F6 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on December 31, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
October 29, 2020 Filed Dec 18, 2020 01:30 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantStock Option (right to buy) · Derivative 2,000,000 $0.00 Strike: $2.41 $0.00
Disclosure

SEC source: 0000899243-20-034342 · doc4.xml · derivative · entry 5

Lecault Veronique · CIK 0001834418 · Director · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Shares · 2,000,000 shares

Expires 2030-10-29

F3 · derivative.exercise_price: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F4 · derivative.exercise_price: The exercise price reported above was converted from the Canadian exercise price of CAD $3.08 using an exchange rate of CAD $1.27840 = US $1.00.

F7 · kind: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F1 · shares: These shares are held by Pacific Swell Capital Corp ("Pacific Swell"). The Reporting Person is a director of Pacific Swell and shares voting and dispositive power with respect to the shares held by Pacific Swell. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.

F5 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 29, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

F3 · derivative.underlying_shares: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F3 · balance_after: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.